- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
4D Molecular Therapeutics Inc (FDMT)
4D Molecular Therapeutics Inc stock price live, this page displays NASDAQ FDMT stock exchange data. View the FDMT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the 4D Molecular Therapeutics Inc real time stock price chart below.
What Is the 4D Molecular Therapeutics Inc Stock Price Today?
The 4D Molecular Therapeutics Inc stock price today is 6.18.
What Is the Stock Symbol for 4D Molecular Therapeutics Inc?
The stock symbol for 4D Molecular Therapeutics Inc is ""FDMT.""
What Stock Exchange Does 4D Molecular Therapeutics Inc Trade On?
4D Molecular Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is 4D Molecular Therapeutics Inc a Good Stock to Buy?
Determining whether 4D Molecular Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FDMT quote. (ISIN: US35104E1001)
What Is the 4D Molecular Therapeutics Inc Stock Price Today?
The 4D Molecular Therapeutics Inc stock price today is 6.18.
What Is the Stock Symbol for 4D Molecular Therapeutics Inc?
The stock symbol for 4D Molecular Therapeutics Inc is ""FDMT.""
What Stock Exchange Does 4D Molecular Therapeutics Inc Trade On?
4D Molecular Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is 4D Molecular Therapeutics Inc a Good Stock to Buy?
Determining whether 4D Molecular Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FDMT quote. (ISIN: US35104E1001)
NASDAQ
Currency in USD
6.18
-0.28(-4.41%)
Real-time Data·
Fair Value
An estimate of a 4D Molecular's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.16
6.73
52 wk Range
2.24
17.41
FDMT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
FDMT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a 4D Molecular's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.166.73
52 wk Range
2.2417.41
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FDMT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a 4D Molecular's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
30.40
Upside
+391.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
4D Molecular Therapeutics Inc Company Profile
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
4D Molecular Therapeutics Inc SWOT Analysis
Gene Therapy Frontie | 4D Molecular Therapeutics advances pivotal trials for wet AMD and DME, showcasing potential to revolutionize ophthalmology treatments with its gene therapy platform |
Financial Fortitude | With $458M cash runway into 2028, FDMT maintains strong liquidity amidst negative cash flow, positioning for long-term pipeline development |
Market Dynamics | Analyst price targets range from $15 to $45, reflecting varied outlooks on FDMT's potential in competitive ophthalmology and cystic fibrosis markets |
Regulatory Landscape | RMAT designation for DME therapy signals promise, while new CBER leadership introduces uncertainty in the evolving gene therapy regulatory environment |
Compare FDMT to Peers and Sector
Metrics to compare | FDMT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFDMTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −2.8x | −0.6x | |
PEG Ratio | 0.03 | 0.01 | 0.00 | |
Price/Book | 0.7x | 0.9x | 2.6x | |
Price / LTM Sales | 8,802.7x | 39.9x | 3.3x | |
Upside (Analyst Target) | - | 115.8% | 38.7% | |
Fair Value Upside | Unlock | 2.2% | 5.1% | Unlock |
Analyst Ratings
9 Buy
2 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 30.40
(+391.91% Upside)
Earnings
Latest Release
Aug 11, 2025
EPS / Forecast
-0.98 / -0.73
Revenue / Forecast
7.10K / 446.89K
People Also Watch
FAQ
What Stock Exchange Does 4D Molecular Trade On?
4D Molecular is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for 4D Molecular?
The stock symbol for 4D Molecular is "FDMT."
What Is the 4D Molecular Market Cap?
As of today, 4D Molecular market cap is 290.02M.
What Is 4D Molecular's Earnings Per Share (TTM)?
The 4D Molecular EPS (TTM) is -3.52.
When Is the Next 4D Molecular Earnings Date?
4D Molecular will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is FDMT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has 4D Molecular Stock Split?
4D Molecular has split 0 times.
How Many Employees Does 4D Molecular Have?
4D Molecular has 227 employees.
What is the current trading status of 4D Molecular (FDMT)?
As of 28 Aug 2025, 4D Molecular (FDMT) is trading at a price of 6.18, with a previous close of 6.46. The stock has fluctuated within a day range of 6.16 to 6.73, while its 52-week range spans from 2.24 to 17.41.
What Is 4D Molecular (FDMT) Price Target According to Analysts?
The average 12-month price target for 4D Molecular is USD30.4, with a high estimate of USD45 and a low estimate of USD10. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +391.91% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.